Angela DM Kashuba
Angela DM Kashuba
UNC Eshelman School of Pharmacy
Verified email at - Homepage
Cited by
Cited by
Preexposure prophylaxis for HIV infection among African women
L Van Damme, A Corneli, K Ahmed, K Agot, J Lombaard, S Kapiga, ...
New England Journal of Medicine 367 (5), 411-422, 2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
NM Archin, AL Liberty, AD Kashuba, SK Choudhary, JD Kuruc, ...
Nature 487 (7408), 482-485, 2012
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method
V ÷zdemir, W Kalow, BK Tang, AD Paterson, SE Walker, L Endrenyi, ...
Pharmacogenetics and Genomics 10 (5), 373-388, 2000
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
ADM Kashuba, AN Nafziger, GL Drusano, JS Bertino Jr
Antimicrobial agents and chemotherapy 43 (3), 623-629, 1999
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients
CA Spina, J Anderson, NM Archin, A Bosque, J Chan, M Famiglietti, ...
PLoS pathogens 9 (12), e1003834, 2013
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission
KB Patterson, HA Prince, E Kraft, AJ Jenkins, NJ Shaheen, JF Rooney, ...
Science translational medicine 3 (112), 112re4-112re4, 2011
Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir
ML Cottrell, T Hadzic, ADM Kashuba
Clinical pharmacokinetics 52, 981-994, 2013
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1
MS Cohen, C Gay, ADM Kashuba, S Blower, L Paxton
Annals of internal medicine 146 (8), 591-601, 2007
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?
MS Cohen, MK Smith, KE Muessig, TB Hallett, KA Powers, AD Kashuba
The Lancet 382 (9903), 1515-1524, 2013
A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without†…
ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone, ...
The Journal of infectious diseases 214 (1), 55-64, 2016
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
NM Archin, R Bateson, MK Tripathy, AM Crooks, KH Yang, NP Dahl, ...
The Journal of infectious diseases 210 (5), 728-735, 2014
Bottlenecks in HIV-1 transmission: insights from the study of founder viruses
SB Joseph, R Swanstrom, ADM Kashuba, MS Cohen
Nature Reviews Microbiology 13 (7), 414-425, 2015
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women
SSA Karim, ADM Kashuba, L Werner, QA Karim
The Lancet 378 (9787), 279-281, 2011
Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis
JB Dumond, RF Yeh, KB Patterson, AH Corbett, BH Jung, NL Rezk, ...
Aids 21 (14), 1899-1907, 2007
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by†…
RF Yeh, VE Gaver, KB Patterson, NL Rezk, F Baxter-Meheux, MJ Blake, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (1), 52-60, 2006
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography–tandem mass spectrometry
BH Jung, NL Rezk, AS Bridges, AH Corbett, ADM Kashuba
Biomedical Chromatography 21 (10), 1095-1104, 2007
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
NM Archin, JL Kirchherr, JAM Sung, G Clutton, K Sholtis, Y Xu, B Allard, ...
The Journal of clinical investigation 127 (8), 3126-3135, 2017
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis
AL Corneli, J Deese, M Wang, D Taylor, K Ahmed, K Agot, J Lombaard, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 66 (3), 324-331, 2014
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1
ADM Kashuba, JR Dyer, LM Kramer, RH Raasch, JJ Eron, MS Cohen
Antimicrobial agents and chemotherapy 43 (8), 1817-1826, 1999
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs
ADM Kashuba, AN Nafziger
Clinical pharmacokinetics 34 (3), 203-218, 1998
The system can't perform the operation now. Try again later.
Articles 1–20